首页> 外国专利> INTERVENTRICULAR DELAY AS A PROGNOSTIC MARKER FOR REVERSE REMODELING OUTCOME FROM CARDIAC RESYNCHRONIZATION THERAPY

INTERVENTRICULAR DELAY AS A PROGNOSTIC MARKER FOR REVERSE REMODELING OUTCOME FROM CARDIAC RESYNCHRONIZATION THERAPY

机译:心室延迟是心律失常同步治疗结果逆转的预后标志

摘要

In heart failure (HF) patients diagnosed according to the New York Heart Association (NYHA) rating scale as either Class III or Class IV, with QRS duration ≥ 120 ms, left ventricular (LV) EF ≤ 35% (when in sinus rhythm), cardiac resynchronization therapy (CRT) can predict sustained improvement in at least LV structure and function. The knowledge of aetiology of a subject's HF status and of a few simple echocardiographic characteristics provides useful information as to whether such patients and undergo significant and beneficial reverse remodelling of the LV in particular and, in the long term can be expected to experience an improvement in all-cause mortality, for example such patients can be reasonably expected to survive and enjoy a relatively enhanced quality of life (QOL). A patient who qualifies according to the invention can be termed a reverse remodelling responder (RRR) or the like.
机译:在根据纽约心脏协会(NYHA)评分量表诊断为心律不齐(HF)的患者中,QRS持续时间≥120 ms,左心室(LV)EF≤35%(窦性心律时)为III级或IV级,心脏再同步治疗(CRT)至少可以预测LV结构和功能的持续改善。受试者的心律状况的病因学知识和一些简单的超声心动图特征可提供有关此类患者是否特别经历LV的显着且有益的反向重塑的有用信息,并且从长远来看,有望改善患者的心律状况全因死亡率,例如可以合理预期此类患者可以生存并享有相对提高的生活质量(QOL)。可以将根据本发明合格的患者称为逆重塑反应者(RRR)等。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号